Opinion|Videos|January 17, 2025
Advancing Multiple Myeloma Care: Insights From ASH 2024 and Beyond
Author(s)Saad Z. Usmani, MD, MBA, FACP, FASCO
Saad Z. Usmani, MD, MBA, FACP, discusses noteworthy data presented at ASH 2024, including the IFM2017-03 trial, and shares his excitement for ongoing research efforts in multiple myeloma, emphasizing key areas where further investigation is needed to improve patient outcomes and refine treatment strategies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please discuss any other data in multiple myeloma released at ASH 2024 that you find noteworthy to share with colleagues.
- Outside of ASH 2024, what ongoing research efforts are you most excited for in the treatment of multiple myeloma, and what are some key areas where you think further research is needed to continue improving patient outcomes?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer
2
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
3
More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor
4
Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis
5